Eb Group Sp. z o.o.
- Address
- Ulica Polna 30b, 00-635 Warsaw, Poland
EB Group Sp. z o.o. - Advanced Inflammatory and Autoimmune Disease Research
EB Group Sp. z o.o. is a specialized clinical research center with extensive expertise in inflammatory bowel diseases and complex autoimmune conditions. The center has established a strong track record in conducting phase 2 and phase 3 clinical trials for novel therapeutic approaches, with particular emphasis on biologic therapies and small molecule interventions targeting chronic inflammatory conditions.
- Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis) - comprehensive research portfolio including induction, maintenance, and long-term extension studies
- Autoimmune and Endocrine Disorders - including thyroid eye disease, Graves' disease, congenital adrenal hyperplasia, and hypoparathyroidism
- Eosinophilic Esophagitis and Chronic Rhinosinusitis - specialized gastrointestinal and upper airway inflammatory conditions
- Rare Disease Research - spinal muscular atrophy, focal segmental glomerulosclerosis, and other complex genetic conditions
The center demonstrates particular proficiency in evaluating novel biologics including anti-IL-23 antibodies, sphingosine 1-phosphate receptor modulators, and other targeted immunomodulatory agents. EB Group's research infrastructure supports complex study designs including adaptive dosing strategies, therapeutic drug monitoring protocols, and comprehensive long-term safety assessments. The center also maintains capabilities in pediatric clinical trials and biosimilar development, positioning it as a versatile research partner for pharmaceutical innovation across multiple therapeutic areas including respiratory conditions, ophthalmology, and metabolic disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Eb Group Sp. z o.o.
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis | Abivax | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Obefazimod | 3 | Unknown | 2023-06-12 | 2023-06-12 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.